[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625301":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":32,"collaborators":7,"id":34,"slug":7,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":56,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Aron Research Foundation Ets","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Matteo Santoni","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Matteo Santoni, Medical Doctor","CONTACT","+39","matteo.santoni82@gmail.com",[19],{"facility":20,"status":7,"city":21,"state":7,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Ospedale di Macerata","Province of Macerata","62100","Italy",{"type":25,"coordinates":26},"Point",[27,28],13.45293,43.29789,{"lat":28,"lon":27},[31],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100625301",false,"NCT07420855","International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la\u002FmUC","International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced\u002FMetastatic Urothelial Cancer (ARON-2PLUS)","ARON-2PLUS","Inclusion Criteria:\n\n* Patients aged \\>18years\n* Histologically confirmed diagnosis of la\u002FmUC of upper and\u002For lower urinary tract or histologically confirmed diagnosis of rare GU tumors.\n* Histologically or radiologically confirmed metastatic disease\n* Patients treated with first-line EV+P combination\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of UC\n* Patients without histologically or radiologically confirmed la or mUC","ALL","18 Years",{"count":44,"type":45},361,"ESTIMATED","OBSERVATIONAL","The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced\u002Fmetastatic Urothelial Cancer.\n\nTwo supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.",[49,50],"Locally Advanced or Metastatic Urothelial Cancer","Urothelial Cancer",[52,53,54,55],"urothelial cancer","pembrolizumab","enfortumab vedotin","rare genitourinary tumors","NOT_YET_RECRUITING","2026-02-12",{"date":59,"type":60},"2026-02-19","ACTUAL",{"date":62,"type":45},"2026-02",{"date":64,"type":45},"2030-12",{"name":5,"class":6},1]